

Figure 14.2.3.1: ACI-91 concentrations in plasma vs. time by patient	2
Figure 14.2.3.2: Mean +/- 1SE of ACI-91 concentrations in plasma vs. time by patient	3
Figure 14.2.3.3: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in biochemical efficacy endpoints	4
Figure 14.2.3.4: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in clinical efficacy endpoints	12
Figure 14.2.3.5: ACI-91 concentrations in CSF vs. time by patient	31
Figure 14.2.3.6: Mean +/- 1SE of ACI-91 concentrations in CSF vs. time by patient	32
Figure 14.2.3.7: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in biochemical efficacy endpoints.....	33
Figure 14.2.3.8: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in clinical efficacy endpoints	41
Figure 14.2.4.1: Albumin CSF/Serum ratio vs. time by patient.....	60
Figure 14.2.4.2: Mean Albumin CSF/Serum ratio vs. time	62

Figure 14.2.3.1: ACI-91 concentrations in plasma vs. time by patient

(page 1 of 1)

07FEB2013

PK Population




Figure 14.2.3.2: Mean +/- 1SE of ACI-91 concentrations in plasma vs. time by patient

(page 1 of 1)

07FEB2013

PK Population




Figure 14.2.3.3: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in biochemical efficacy endpoints (page 1 of 8)

07FEB2013

PK Population




Figure 14.2.3.3: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in biochemical efficacy endpoints
(page 2 of 8)

07FEB2013

PK Population




Figure 14.2.3.3: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in biochemical efficacy endpoints
(page 3 of 8)

07FEB2013

PK Population




Figure 14.2.3.3: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in biochemical efficacy endpoints
(page 4 of 8)

07FEB2013

PK Population




Figure 14.2.3.3: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in biochemical efficacy endpoints (page 5 of 8)

07FEB2013

PK Population




Figure 14.2.3.3: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in biochemical efficacy endpoints
(page 6 of 8)

07FEB2013

PK Population




Figure 14.2.3.3: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in biochemical efficacy endpoints
(page 7 of 8)

07FEB2013

PK Population




Figure 14.2.3.3: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in biochemical efficacy endpoints
(page 8 of 8)

07FEB2013

PK Population





Figure 14.2.3.4: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in clinical efficacy endpoints (page 1 of 19)

07FEB2013

PK Population



Controlled Oral Word Association Test (COWAT) – FAS

Figure 14.2.3.4: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in clinical efficacy endpoints (page 2 of 19)

07FEB2013

PK Population





Figure 14.2.3.4: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in clinical efficacy endpoints (page 3 of 19)

07FEB2013

PK Population




Trail Making Tests A (TMA) and B (TMB)

Figure 14.2.3.4: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in clinical efficacy endpoints
(page 4 of 19)

07FEB2013

PK Population




Trail Making Tests A (TMA) and B (TMB)

Figure 14.2.3.4: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in clinical efficacy endpoints
(page 5 of 19)

07FEB2013

PK Population



Simple Reaction Time (SRT)

Figure 14.2.3.4: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in clinical efficacy endpoints
(page 6 of 19)

07FEB2013

PK Population




Figure 14.2.3.4: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in clinical efficacy endpoints (page 7 of 19)

07FEB2013

PK Population





Figure 14.2.3.4: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in clinical efficacy endpoints (page 8 of 19)

07FEB2013

PK Population




Wechsler Verbal Paired Associates Test (WVPAT) Paired Associative Learning

Figure 14.2.3.4: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in clinical efficacy endpoints (page 9 of 19)

07FEB2013

PK Population




Wechsler Verbal Paired Associates Test (WVPAT) Paired Associative Learning

Figure 14.2.3.4: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in clinical efficacy endpoints
(page 10 of 19)

07FEB2013

PK Population




Wechsler Verbal Paired Associates Test (WVPAT) Paired Associative Learning

Figure 14.2.3.4: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in clinical efficacy endpoints
(page 11 of 19)

07FEB2013

PK Population




Wechsler Verbal Paired Associates Test - delayed (WVPATd) Paired Associative Learning

Figure 14.2.3.4: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in clinical efficacy endpoints
(page 12 of 19)

07FEB2013

PK Population




Alzheimers Disease Assessment Scale (ADAS-cog)

Figure 14.2.3.4: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in clinical efficacy endpoints
(page 13 of 19)

07FEB2013

PK Population




Alzheimers Disease Assessment Scale (ADAS-cog)

Figure 14.2.3.4: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in clinical efficacy endpoints (page 14 of 19)

07FEB2013

PK Population



Mini-Mental State Examination (MMSE)

Figure 14.2.3.4: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in clinical efficacy endpoints
(page 15 of 19)

07FEB2013

PK Population





Figure 14.2.3.4: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in clinical efficacy endpoints
(page 16 of 19)

07FEB2013

PK Population




Clinical Dementia Rating (CDR) Sum of Boxes Rating Scale

Figure 14.2.3.4: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in clinical efficacy endpoints (page 17 of 19)

07FEB2013

PK Population




Disability Assessment in Dementia (DAD) Scale

Figure 14.2.3.4: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in clinical efficacy endpoints (page 18 of 19)

07FEB2013

PK Population




Disability Assessment – Neuropsychiatric Inventory (NPI)

Figure 14.2.3.4: Scatter plot of change from baseline in ACI-91 in plasma vs. change from baseline in clinical efficacy endpoints
(page 19 of 19)

07FEB2013

PK Population



Disability Assessment – Neuropsychiatric Inventory (NPI)

Figure 14.2.3.5: ACI-91 concentrations in CSF vs. time by patient

(page 1 of 1)

07FEB2013

PK Population




Figure 14.2.3.6: Mean +/- 1SE of ACI-91 concentrations in CSF vs. time by patient

(page 1 of 1)

07FEB2013

PK Population




Figure 14.2.3.7: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in biochemical efficacy endpoints (page 1 of 8)

07FEB2013

PK Population




Figure 14.2.3.7: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in biochemical efficacy endpoints (page 2 of 8)

07FEB2013

PK Population




Figure 14.2.3.7: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in biochemical efficacy endpoints (page 3 of 8)

07FEB2013

PK Population




Figure 14.2.3.7: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in biochemical efficacy endpoints
(page 4 of 8)

07FEB2013

PK Population




Figure 14.2.3.7: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in biochemical efficacy endpoints (page 5 of 8)

07FEB2013

PK Population




Figure 14.2.3.7: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in biochemical efficacy endpoints (page 6 of 8)

07FEB2013

PK Population




Figure 14.2.3.7: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in biochemical efficacy endpoints (page 7 of 8)

07FEB2013

PK Population




Figure 14.2.3.7: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in biochemical efficacy endpoints (page 8 of 8)

07FEB2013

PK Population





Figure 14.2.3.8: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in clinical efficacy endpoints (page 1 of 19)

07FEB2013

PK Population



Controlled Oral Word Association Test (COWAT) – FAS

Figure 14.2.3.8: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in clinical efficacy endpoints (page 2 of 19)

07FEB2013

PK Population





Figure 14.2.3.8: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in clinical efficacy endpoints (page 3 of 19)

07FEB2013

PK Population



Trail Making Tests A (TMA) and B (TMB)

Figure 14.2.3.8: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in clinical efficacy endpoints (page 4 of 19)

07FEB2013

PK Population




Figure 14.2.3.8: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in clinical efficacy endpoints (page 5 of 19)

07FEB2013

PK Population




Figure 14.2.3.8: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in clinical efficacy endpoints (page 6 of 19)

07FEB2013

PK Population




Figure 14.2.3.8: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in clinical efficacy endpoints (page 7 of 19)

07FEB2013

PK Population





Figure 14.2.3.8: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in clinical efficacy endpoints (page 8 of 19)

07FEB2013

PK Population




Wechsler Verbal Paired Associates Test (WVPAT) Paired Associative Learning

Figure 14.2.3.8: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in clinical efficacy endpoints (page 9 of 19)

07FEB2013

PK Population




Wechsler Verbal Paired Associates Test (WVPAT) Paired Associative Learning

Figure 14.2.3.8: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in clinical efficacy endpoints (page 10 of 19)

07FEB2013

PK Population




Wechsler Verbal Paired Associates Test (WVPAT) Paired Associative Learning

Figure 14.2.3.8: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in clinical efficacy endpoints (page 11 of 19)

07FEB2013

PK Population



Wechsler Verbal Paired Associates Test – delayed (WVPATd) Paired Associative Learning

Figure 14.2.3.8: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in clinical efficacy endpoints
(page 12 of 19)

07FEB2013

PK Population




Figure 14.2.3.8: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in clinical efficacy endpoints
(page 13 of 19)

07FEB2013

PK Population




Figure 14.2.3.8: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in clinical efficacy endpoints
(page 14 of 19)

07FEB2013

PK Population




Figure 14.2.3.8: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in clinical efficacy endpoints
(page 15 of 19)

07FEB2013

PK Population





Figure 14.2.3.8: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in clinical efficacy endpoints
(page 16 of 19)

07FEB2013

PK Population




Clinical Dementia Rating (CDR) Sum of Boxes Rating Scale

Figure 14.2.3.8: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in clinical efficacy endpoints (page 17 of 19)

07FEB2013

PK Population




Disability Assessment in Dementia (DAD) Scale

Figure 14.2.3.8: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in clinical efficacy endpoints (page 18 of 19)

07FEB2013

PK Population




Disability Assessment – Neuropsychiatric Inventory (NPI)

Figure 14.2.3.8: Scatter plot of change from baseline in ACI-91 in CSF vs. change from baseline in clinical efficacy endpoints
(page 19 of 19)

07FEB2013

PK Population



Disability Assessment – Neuropsychiatric Inventory (NPI)

Figure 14.2.4.1: Albumin CSF/Serum ratio vs. time by patient

(page 1 of 2)

07FEB2013

PK Population




Figure 14.2.4.1: Albumin CSF/Serum ratio vs. time by patient

(page 2 of 2)

07FEB2013

PK Population




Figure 14.2.4.2: Mean Albumin CSF/Serum ratio vs. time

(page 1 of 2)

07FEB2013

PK Population




Figure 14.2.4.2: Mean Albumin CSF/Serum ratio vs. time

(page 2 of 2)

07FEB2013

PK Population

